That includes the recent decision to reject NHS use of AZ and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) for HER2-low ...
There was a standoff between USAID and Elon Musk's Department of Government Efficiency (DOGE) over access to restricted areas ...
Roche is the recipient of the new approval, getting the go-ahead from the US regulator for its PATHWAY HER2 (4B5) test to ...
Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing ...
Researchers in Europe have called for action to safeguard the independence of patient organisations, after finding potential for a "hidden conflict of interest" in a study. The team from the ...
Grifols has filed for US approval of a new drug for rare bleeding disorder acquired fibrinogen deficiency (AFD), which promises to provide a more reliable and easier treatment for patients.
Every day, thousands worldwide find out they have a disease or health condition that requires care. And each day more and more people don’t get the care they need because they don’t understand ...
Chipmaker Advanced Micro Devices (AMD) has followed in the footsteps of its arch-rival NVIDIA and started to build a presence in artificial intelligence-powered drug discovery – starting with a ...
With the Federal Reserve poised to implement interest rate cuts (albeit fewer than earlier forecasts assumed) and FTC leadership turnover anticipated, there may be broader shifts in how capital is ...
Healthcare is transitioning to a patient-centric approach and healthcare consumerism. Patients have fast become consumers first, with the freedom to make decisions about their health journeys, and ...
The FDA has responded to the increasing use of artificial intelligence (AI) in the discovery and development of drugs and biologics by publishing its first provisional guidance on the technology's ...
Ozempic/Wegovy is the first drug on HHS's 2025 list of Medicare price negotiations. As the leaders of the pharmaceutical industry boarded their planes to come home from the JP Morgan Healthcare ...